Zimmer Biomet Holdings Inc. ($ZBH) Stock Forecast: Down 3.2% Today

What is Zimmer Biomet Holdings Inc.?

Zimmer Biomet Holdings Inc. (ZBH) operates in the medical equipment sector, specializing in robotic surgery technologies. The stock experienced a decline of 1.27% today, reaching $84.41 and closing notably below its 52-week high.

Why is Zimmer Biomet Holdings Inc. going down?

ZBH stock is down 3.2% on May 27, 2026 16:36

• Adjusted Zimmer Biomet's price target slightly upwards but maintained a Sell rating.
• Despite positive fiscal Q1 results and ongoing transformation efforts, recent price target cuts and analyst downgrades affected the stock's performance.
• Institutional interest from Northwestern Mutual Wealth Management Co. and positive Q4 earnings were outweighed by slowing organic revenue growth and operational challenges identified in the SWOT analysis.
• The delayed commercialization of the autonomous robotics platform and the reliance on new product launches for growth may have led to investor doubt and the stock's bearish movement today.

ZBH Price Chart

ZBH Technical Analysis

ZBH News

Goldman Sachs Adjusts PT on Zimmer Biomet to $87 From $86, Maintains Sell Rating

Goldman Sachs has adjusted its price target for Zimmer Biomet to $87, a slight increase from the previous $86. Despite this change, the firm has decided to maintain its Sell rating on the company. This indicates that while there might be a marginal increase in the perceived value, Goldman Sachs still advises investors to sell Zimmer Biomet stock.

https://www.moomoo.com/news/post/70632082/goldman-sachs-adjusts-pt-on-zimmer-biomet-to-87-from?futusource=news_newspage_recommend

Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors

Zimmer Biomet Holdings Inc. (ZBH) stock fell 1.27% to $84.41 on Tuesday, underperforming its competitors. This occurred on a mixed trading day where the S&P 500 rose, but the Dow Jones Industrial Average fell. The company's stock closed 22.05% below its 52-week high.

https://www.marketwatch.com/data-news/zimmer-biomet-holdings-inc-stock-underperforms-tuesday-when-compared-to-competitors-cafe45ae-7ecfb453c094

Is Zimmer Biomet Holdings (ZBH) One of the Best Robotic Surgery Stocks to Buy?

Zimmer Biomet Holdings (ZBH) is highlighted as a top robotic surgery stock, despite recent price target cuts from Canaccord and Citizens. Both firms maintained positive ratings, acknowledging the company's solid fiscal Q1 performance and ongoing go-to-market transformation. The article notes ZBH delivered stronger EPS and a modest revenue beat, partially due to tariff-related benefits, and it raised EPS guidance while affirming its revenue outlook for what is seen as a transitional year.

https://www.insidermonkey.com/blog/is-zimmer-biomet-holdings-zbh-one-of-the-best-robotic-surgery-stocks-to-buy-1768748/

Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, reflecting institutional interest in the medical equipment provider. The company reported strong Q4 earnings, beating revenue and EPS expectations, and issued positive guidance for FY2026. Despite a "Hold" consensus rating from analysts, some have reiterated "buy" ratings, and the stock offers a quarterly dividend.

https://www.marketbeat.com/instant-alerts/filing-zimmer-biomet-holdings-inc-zbh-shares-purchased-by-northwestern-mutual-wealth-management-co-2026-05-26/

Zimmer Biomet’s SWOT analysis: stock faces growth headwinds

Zimmer Biomet Holdings (NYSE: ZBH) is facing growth headwinds, highlighted by slowing organic revenue growth and analyst downgrades. Despite strategic initiatives like salesforce restructuring and autonomous robotics development, the company's fiscal year 2025 saw a 14.8% stock decline, with analysts maintaining a cautious outlook due to underperforming acquisitions and increased operational expenditures. While the autonomous robotics platform offers long-term competitive advantages, its commercialization isn't expected until late 2027 or early 2028, meaning near-term growth relies on new product launches and the effectiveness of current restructuring programs.

https://www.investing.com/news/swot-analysis/zimmer-biomets-swot-analysis-stock-faces-growth-headwinds-93CH-4708561

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Zimmer Biomet Holdings Inc. Price History

13.00.2026 - ZBH Stock was down 2.3%

• During the third quarter of 2025, Nisa Investment Advisors LLC notably decreased its ownership in Zimmer Biomet Holdings, Inc. by 39.8%, potentially indicating a lack of faith in the company's upcoming performance, which might have contributed to the recent market decline.
• Zimmer Biomet Holdings Inc. demonstrated weaker performance compared to its industry counterparts, potentially due to factors beyond what has been publicly revealed, fostering a pessimistic market mood.
• The departure of Mark Bezjak, a vital executive at Zimmer Biomet Holdings, triggered concerns among shareholders regarding leadership stability and future strategic plans, adversely affecting the stock value.
• Following Mark R. Bezjak's appointment at Dentsply Sirona, where he previously held leadership positions at Zimmer Biomet, investors may have grown uneasy about potential competitive shifts towards a rival firm, leading to the downturn in Zimmer Biomet's stock price.

10.01.2026 - ZBH Stock was up 5.3%

• Strong fourth-quarter financial results from Zimmer Biomet exceeded revenue and earnings predictions, leading to the stock's upward trend.
• Despite the positive results, the company's cautious approach to its 2026 guidance, citing the ever-changing healthcare landscape, initially caused a slight decline in pre-market stock prices.
• The strategic shift towards a direct and specialized sales model in the U.S., as highlighted by the CEO, likely bolstered investor confidence in the company's future growth.
• A newly announced $1.5 billion stock repurchase program also contributed to positive investor sentiment and the stock's upward trajectory.

29.03.2026 - ZBH Stock was down 6.8%

• Despite reporting strong Q1 2026 results and surpassing earnings expectations, Zimmer Biomet Holdings experienced a bearish trend, likely driven by investors taking profits following a period of positive performance.
• Activities of various analysts, including adjustments in price targets and ratings by JPMorgan and Goldman Sachs, might have impacted market sentiment and contributed to the bearish movement.
• The resignation of CFO Suky Upadhyay may have sparked concerns among investors regarding potential internal changes or challenges within the company, leading to a negative impact on the stock price.
• The broader market sentiment towards medical device companies, exemplified by Mitsubishi UFJ Trust & Banking Corp reducing its stake in Edwards Lifesciences Corporation, could have also played a role in influencing the stock performance of ZBH.

11.04.2026 - ZBH Stock was down 2.1%

• Today, ZBH's stock witnessed a notable downward trend for various reasons:
• Strong quarterly results and an improved earnings per share projection were overshadowed by ongoing investor concerns, resulting in a lack of trust among shareholders.
• The substantial sale of shares by Bryn Mawr Trust Advisors LLC likely contributed to the stock's decline, indicating a decrease in investor interest.
• Following the Chief Financial Officer's departure, the stock price dropped, leading to apprehensions about leadership stability and potential financial performance, influencing investor confidence.
• Despite ZBH's robust Q1 performance, the prevailing market view that the stock may be undervalued might have prompted profit-taking activities and selling pressure, prompting the bearish movement.

14.00.2026 - ZBH Stock was down 5.2%

• ZBH shares exhibited a significant drop following the company's conservative statements about its future at the J.P. Morgan Healthcare Conference, reflecting concerns among investors about its upcoming performance.
• Despite the recent bearish market movement, evaluations still consider Zimmer Biomet a worthwhile investment opportunity, supported by favorable valuation metrics and financial stability. This indicates that short-term apprehensions may be overshadowing its long-term prospects.
• The decision from Nisa Investment Advisors LLC to sell ZBH shares, alongside other institutional investors increasing their holdings, could have amplified the selling pressure, contributing to the downward trend.
• The recent appointment of Mark R. Bezjak as Group Vice President at Dentsply Sirona, who had a prior role at Zimmer Biomet, might have indirectly influenced the market sentiment towards ZBH, prompting investors to evaluate potential implications on competitiveness and industry dynamics.

04.01.2026 - ZBH Stock was up 2.8%

• ZBH stock experienced a strong bullish movement recently.
• Positive market sentiment was fueled by expectations of increased earnings and higher revenues for the quarter ending December 2025.
• Despite some analyst revisions and a negative Earnings ESP, optimistic growth projections and the company's robust fundamentals likely boosted investor confidence.
• The increase in stake by the National Pension Service and the company's solid reputation as a reliable dividend cornerstone might have positively impacted the stock's performance.

27.04.2026 - ZBH Stock was down 3.2%

• Adjusted Zimmer Biomet's price target slightly upwards but maintained a Sell rating.
• Despite positive fiscal Q1 results and ongoing transformation efforts, recent price target cuts and analyst downgrades affected the stock's performance.
• Institutional interest from Northwestern Mutual Wealth Management Co. and positive Q4 earnings were outweighed by slowing organic revenue growth and operational challenges identified in the SWOT analysis.
• The delayed commercialization of the autonomous robotics platform and the reliance on new product launches for growth may have led to investor doubt and the stock's bearish movement today.

28.03.2026 - ZBH Stock was down 7.7%

• Experienced a strong bearish movement today.
• The departure of the Chief Financial Officer, Suketu Upadhyay, and the appointment of an interim CFO may have caused uncertainty and investor concern.
• The market reacted negatively to the CFO transition, possibly interpreting it as a potential disruption to Zimmer Biomet's growth and margin initiatives.
• Investors may be monitoring the situation closely for any further developments or announcements regarding the company's financial leadership.

28.03.2026 - ZBH Stock was down 10.1%

• Zimmer Biomet Holdings Inc. is a medical device company that focuses on designing, manufacturing, and marketing orthopedic reconstructive products. The company operates globally, with a strong presence in the medical technology market.
• Recently, ZBH stock dropped by about 6% due to various factors.
• The departure of the CFO and the company's reaffirmation of its full-year revenue outlook in the Q1 report led to the largest single-day decline in the stock since November.
• Investor sentiment may have been impacted by uncertainty regarding leadership changes and their potential effects on financial performance.
• Investors are closely following Zimmer Biomet's growth and margin strategies, particularly in the medical technology sector, amidst ongoing changes in top leadership roles.

28.03.2026 - ZBH Stock was down 6.7%

• Following the departure of the CFO, Suketu Upadhyay, despite the positive financial outcomes and upgraded full-year guidance, investor uncertainty emerged, triggering a downward trend in the stock price.
• The market's response to the appointment of an interim CFO and the impending search for a permanent successor is viewed as a potential risk factor to the company's future financial performance.
• The prevailing bearish momentum might also be influenced by profit-taking actions subsequent to the strong earnings disclosure, prompting investors to review the stock's valuation and growth prospects in the medical technology sector.

14.03.2026 - ZBH Stock was up 5.3%

• The bullish movement in ZBH stock can be attributed to positive analyst coverage and market sentiment surrounding the company's resilience in navigating supply chain challenges in the medtech industry.
• Analysts' cautiously optimistic views, particularly from Leerink Partners initiating coverage with a Market Perform rating and a price target of $101.00, have likely bolstered investor confidence in Zimmer Biomet's long-term growth prospects.
• The company's recent surpassing of Q4 earnings expectations and strategic restructuring, including the launch of new products like the mBôs robot, have also contributed to the positive momentum in its stock price.
• Despite potential near-term growth limitations due to market dynamics, ZBH's strong balance sheet, leadership in robotics, and focus on addressing supply chain disruptions position it favorably for sustained gains in the future.

05.10.2025 - ZBH Stock was down 15.5%

• Despite Zimmer Biomet exceeding Q3 earnings forecasts, the stock faced a decline in revenue and a reduced outlook, resulting in an early slide.
• Challenges in Latin America and select EU markets affected the company's projected organic growth, contributing to the stock's downward trend.
• The stock price dropped by 0.84% in the latest market session, marking a significant 9.34% decrease over the past year.
• Zimmer Biomet Holdings Inc.'s short interest as a percentage of float has increased, indicating a rise in bearish sentiment among investors.